Kintara announces 1-for-35 reverse stock split in connection with TuHURA merger

Kintara Therapeutics (KTRA) announced that its board of directors has approved a reverse stock split of Kintara’s common stock at a ratio of 1-for-35. Kintara’s common stock is expected to begin trading on a post-reverse stock split basis on the Nasdaq Capital Market on October 18, under the new name TuHURA Biosciences, Inc. and under the new symbol “HURA” following the anticipated closing of the merger with TuHURA, the company stated. Following the closing of the merger, the combined company’s total outstanding common stock is expected to be approximately 42.0M shares. TuHURA Biosciences is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda in first line treatment for advanced Merkel Cell Carcinoma.